BANK OF AMERICA CORP /DE/ - MABVAX THERAPEUTICS HLDGS IN ownership

MABVAX THERAPEUTICS HLDGS IN's ticker is MBVX and the CUSIP is 55414P504. A total of 15 filers reported holding MABVAX THERAPEUTICS HLDGS IN in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
BANK OF AMERICA CORP /DE/ ownership history of MABVAX THERAPEUTICS HLDGS IN
ValueSharesWeighting
Q4 2017$13,000
+8.3%
18,9960.0%0.00%
Q3 2017$12,000
-53.8%
18,9960.0%0.00%
Q2 2017$26,00018,996
+1899500.0%
0.00%
Q1 2017$010.0%0.00%
Q4 2016$010.00%
Other shareholders
MABVAX THERAPEUTICS HLDGS IN shareholders Q4 2017
NameSharesValueWeighting ↓
Cambridge Investment Research Advisors, Inc. 3,058,703$2,141,0000.02%
Biomark Capital Management Co. LLC 26,708$19,0000.02%
Delaney Dennis R 10,000$7,0000.01%
Bison Wealth, LLC 15,000$11,0000.01%
Virtu Financial LLC 99,114$69,0000.00%
BRIGHTON JONES LLC 10,000$7,0000.00%
BANK OF AMERICA CORP /DE/ 18,996$13,0000.00%
WELLS FARGO & COMPANY/MN 3$00.00%
DEUTSCHE BANK AG\ 3$00.00%
Brinker Capital Investments, LLC 1,000$1,0000.00%
View complete list of MABVAX THERAPEUTICS HLDGS IN shareholders